Inhibition of growth signalling receptors such as human epidermal growth factor receptor 2 (HER2) has shown some success in the treatment of breast cancer especially in patients with chemotherapy resistant metastatic disease (Baselga et al. 1996; Cobleigh et al. 1999). Here, ERBB2 is linked to breast cancer.